Relationship between serum IgG4 levels and clinical activity of ophthalmopathy in Graves’ disease Authors: Doğan Mengeş, Ahu Yılmaz, Özlem Doğan, Feyza Önder Published: 2026 ABSTRACT AbstractPurposeThe aim of this study was to evaluate the association between serum IgG4 levels and the presence, activity, and severity of thyroid eye disease (TED) within a single cohort of patients with Graves’ disease, and to assess the potential role of IgG4 as a complementary biomarker across the clinical spectrum of the disease.MethodsThis cross-sectional study included 46 patients diagnosed with Graves’ disease, comprising 23 patients with TED and 23 without TED. All participants underwent a comprehensive ophthalmological and biochemical evaluation, including thyroid function testing, autoantibody profiling, and measurement of serum total IgG, IgG4, and the IgG4/IgG ratio. Disease activity was assessed using the Clinical Activity Score (CAS ≥ 3), and disease severity was classified according to the European Group on Graves’ Orbitopathy (EUGOGO) criteria.ResultsSerum IgG4 levels were significantly higher in TED patients than in those without TED (97.7 ± 92.6 vs. 52.9 ± 42.9 mg/dL; p = 0.041). The IgG4/IgG ratio was also increased (8.05 ± 6.75% vs. 4.44 ± 3.42%; p = 0.027). Moderate-to-severe TED showed higher IgG4 and IgG4/IgG values than mild disease (p = 0.042 and p = 0.041). Active TED had greater IgG4 levels than inactive cases (132.0 ± 112.1 vs. 60.2 ± 45.4 mg/dL; p = 0.049). IgG4 correlated positively with activity and severity. The proportion of patients with IgG4 ≥ 135 mg/dL was 8.7% in patients without TED and 21.7% in those with TED, with higher proportions particularly observed in active and moderate-to-severe cases.ConclusionElevated serum IgG4 levels in TED were associated with the presence, activity, and severity of the disease. These findings suggest that serum IgG4 may reflect underlying immunological activity across the TED spectrum. Measurement of serum IgG4 may serve as a complementary biomarker to conventional clinical scoring systems in the assessment of disease activity and severity. To clarify the clinical significance and temporal dynamics of these associations, large-scale prospective and longitudinal studies incorporating imaging and tissue-based evaluations are warranted.Keywords: Thyroid eye disease, IgG4, Immune biomarker Introduction Graves’ disease is an autoimmune endocrine disorder caused by autoantibodies directed against the thyroid-stimulating hormone receptor (TSHR) [1]. Although it appears to be specific to the thyroid gland, the TSH receptor is expressed not only in thyroid tissue but also in fibroblasts, adipocytes, and extraocular muscle cells [2]. Therefore, Graves’ disease represents a complex autoimmune process that may exhibit systemic manifestations. The most common and clinically prominent extrathyroidal manifestation of the disease is thyroid eye disease (TED). [3–4]. TED begins with the activation of orbital fibroblasts and preadipocytes through stimulation of the TSH receptor (TSHR) and the insulin-like growth factor-1 (IGF-1) receptor. This activation leads to inflammation, edema, fibrosis, and increased tissue volume within the orbital tissues, mediated by cytokines, chemokines, and autoantibodies. Both cellular and humoral immune responses play important roles in the pathogenesis of the disease. However, the precise mechanisms underlying these processes have not yet been fully elucidated [5]. Recent studies have suggested that the immunoglobulin G4 (IgG4) subclass may also play a role in the development of TED. [6–7] IgG4 is an antibody subclass that may show increased levels in conditions characterized by chronic antigenic stimulation [8]. This antibody is characteristically elevated in a systemic fibroinflammatory disease group defined as IgG4-related disease (IgG4-RD) [9]. IgG4-RD can involve multiple organs, including the thyroid and the orbit; in this context, the term “IgG4-related orbital disease (IgG4-ROD)” has also been described in the literature [10]. There are notable clinical, histopathological, and immunological similarities between IgG4-related orbital disease (IgG4-ROD) and TED. In both conditions, lymphoplasmacytic infiltration, fibroblast activation, and fibrotic changes are observed. Some studies have reported that serum IgG4 levels are significantly higher in patients with Graves’ disease compared with the normal population and that this increase may be associated with disease activity or severity [6, 11]. However, findings in this area remain conflicting. While some studies have demonstrated a significant correlation between serum IgG4 levels and clinical activity, [12–13] others have failed to confirm this association [14]. These discrepancies have raised the question of whether increased IgG4 levels in Graves’ disease are associated with the natural course and clinical characteristics of the disease. In addition, whether elevated IgG4 levels may serve as a biomarker during the development and progression of TED remains a subject worthy of investigation. This study aims to evaluate the association between serum IgG4 levels and the development of TED, as well as disease activity and severity, in individuals diagnosed with Graves’ disease. Within this framework, two main hypotheses were tested: TED development hypothesis: Serum IgG4 levels are higher in patients who develop TED than in those who do not. TED development hypothesis: Serum IgG4 levels are higher in patients who develop TED than in those who do not. Activity and severity hypothesis: Serum IgG4 levels are positively associated with clinical activity, as assessed by the Clinical Activity Score (CAS), and with disease severity. Activity and severity hypothesis: Serum IgG4 levels are positively associated with clinical activity, as assessed by the Clinical Activity Score (CAS), and with disease severity. In this respect, the present study represents one of the original datasets evaluating the relationship between serum IgG4 levels and the presence of TED, clinical activity, and disease severity within the same Graves’ disease cohort, and offers a novel perspective on the immunological features associated with the clinical activity and severity of TED. Methods Study design and participants This cross-sectional study was conducted among patients diagnosed with Graves’ disease who were followed at the Endocrinology Outpatient Clinic of University of Health Sciences Haseki Training and Research Hospital and were referred to the Ophthalmology (Oculoplastic) Unit for evaluation of TED between December 2023 and January 2024. A total of 46 patients with Graves’ disease were included in the study, comprising 23 patients with TED and 23 patients without TED. Eligible participants were adults aged 18 years or older with a confirmed diagnosis of Graves’ disease based on clinical, laboratory, and radiological evaluations. Exclusion criteria included the presence of systemic diseases that could affect serum biochemical parameters (such as chronic liver or kidney failure, collagen tissue diseases, or malignancy), use of systemic corticosteroids or immunosuppressive therapy within the previous six months, a history of bacterial or viral infection within the preceding week, a history of atopic disease, pregnancy, and age under 18 years. Clinical assessment For all patients, data on age, sex, smoking status, history of systemic diseases, duration of Graves’ disease, thyroid functional status (hyperthyroid, hypothyroid, euthyroid), administered treatments (methimazole, propylthiouracil, levothyroxine), and history of thyroidectomy or radioactive iodine therapy were recorded. Patients who developed TED were additionally evaluated for a history of orbital radiotherapy, systemic corticosteroid therapy, or surgical treatment. Ophthalmological examination All participants underwent a comprehensive ophthalmological evaluation. Best-corrected visual acuity (BCVA) was assessed using the Snellen chart. Intraocular pressure (IOP) was measured using a non-contact tonometer, with the mean value of three consecutive measurements recorded. Proptosis was assessed using a Hertel exophthalmometer. Color vision was evaluated using Ishihara plates, and pupillary reactions were assessed by light reflex testing. The presence of a relative afferent pupillary defect (RAPD) was examined using the swinging flashlight test. When evaluating eyelid position, visible sclera above the limbus in the upper eyelid and the presence of scleral show in the lower eyelid were considered indicative of eyelid retraction. The presence of diplopia was assessed by questioning patients in different gaze positions. All patients additionally underwent slit-lamp biomicroscopic anterior segment examination and fundus examination following pupil dilation. Assessment of disease activity and severity Patients who developed TED were classified according to the CAS and the criteria of the European Group on Graves’ Orbitopathy (EUGOGO). The CAS consists of seven parameters (spontaneous retrobulbar pain, pain on eye movement, eyelid erythema, eyelid edema, diffuse conjunctival hyperemia, chemosis, and edema of the caruncle or plica), with a score of 3 or higher considered indicative of active disease. Disease severity was graded as mild or moderate-to-severe according to the EUGOGO criteria. No patients were classified as having sight-threatening disease. This classification approach was adopted to allow separate evaluation of the association between serum IgG4 levels and not only the presence of TED, but also disease activity and severity. All patients in the TED group underwent contrast-enhanced orbital magnetic resonance imaging (MRI) to confirm the diagnosis and to assess extraocular muscle involvement. Extraocular muscle involvement was defined by muscle thickening on T1-weighted sequences and the presence of inflammation-related edema on T2-weighted sequences. Laboratory examinations Fasting venous blood samples were collected from the antecubital vein of all patients. Biochemistry, complete blood count, erythrocyte sedimentation rate, CRP, hepatitis markers, thyroid function tests (TSH, free T3, free T4), thyroid autoantibodies (TRAb, anti-TPO, anti-Tg), total IgG, and IgG subclasses were analyzed in the Biochemistry Laboratory of Haseki Training and Research Hospital. IgG4 measurement Serum IgG4 levels were measured in samples collected and processed in accordance with standard laboratory protocols using a validated nephelometric method. Measurements were performed with a Siemens BN II nephelometer (Siemens AG, Munich, Germany) using the Siemens N Latex IgG4 kit, and results were reported in mg/dL. The laboratory reference range for serum IgG4 in adults was defined as 3–201 mg/dL. Statistical analyses Sample size was calculated using G*Power software (v3.1.6). All statistical analyses were performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL). The primary variable was the group difference in serum IgG4 levels; α = 0.05, effect size (Cohen’s d) = 0.6, and 85% power indicated a minimum of 40 participants. A total of 46 patients (23 TED, 23 non-TED) were included, and the sample size was deemed sufficient. Descriptive statistics were expressed as number (n) and percentage (%) for categorical variables, and as mean ± standard deviation (SD) or median (min–max) for continuous variables. Student-t test was used for normally distributed variables, and Mann–Whitney U test for non-normally distributed variables. Categorical variables were analyzed with chi-square test. Correlations between continuous variables were tested using Pearson or Spearman correlation analysis. A p-value ≤ 0.05 was considered statistically significant. Results Laboratory parameters of the patient groups are summarized in Table 1. TRAb levels were found to be significantly higher in patients who developed TED (6.98 ± 10.95 IU/L) compared to those who did not develop TED (2.29 ± 2.28 IU/L), and this difference was statistically significant (p = 0.050). Serum IgG4 levels were significantly increased in the TED group, with a mean value of 97.67 ± 92.57 mg/dL, whereas the mean value was 52.90 ± 42.92 mg/dL in the non-TED group (p = 0.041)(Fig. 1). In contrast, there was no significant difference in total IgG levels between the groups (p = 0.637). When the IgG4/IgG ratio was evaluated, this ratio was found to be significantly higher in patients who developed TED (8.05 ± 6.75% vs. 4.44 ± 3.42%; p = 0.027). The proportion of patients with serum IgG4 ≥ 135 mg/dL was 8.7% (n = 2) in the non-TED group and 21.7% (n = 5) in the TED group; however, this difference was not statistically significant (p = 0.218). Table 1Laboratory valuesGRAVES’ DISEASEGD without TED (n = 23)GD with TED (n = 23)Mean ± SD (Min–Max)Mean ± SD (Min–Max)pFree T3 ng/L3,84 ± 2,13 (2,10 − 9,93)5,19 ± 4,49 (1,72 − 18,7)0,318**Free T4 ng/L14,44 ± 6,52 (8,48 − 35,30)14,84 ± 9,56 (3,95 − 47)0,792**TSH mU/L1,75 ± 2,31 (0,01–8,76)3,32 ± 7,40 (0,01–26,6)0,540** TRAb IU/L 2,29 ± 2,28 (0,1–10,70)6,98 ± 10,95 (0,1–40)0,050**Anti-TPO kU/L127,87 ± 144,71(9-559)194,32 ± 190,35 (9-600)0,284**Anti-TG kU/L170,85 ± 199,04 (10,1-616)827,24 ± 1312,38 (12,1-4000)0,060** Serum IgG4 mg/dL 52,90 ± 42,92 (0,6-148)97,67 ± 92,57 (0,6-380)0,041**Total IgG mg/dL1192,83 ± 190,1 (916–1720)1232,17 ± 246,75 (768–1710)0,637** IgG4/IgG Total (%) 4,44 ± 3,42 (0,05–11,21)8,05 ± 6,75 (0,05–23,09)0,027**≥ 135 IgG4 mg/dL n(%)2 (8,7)5 (21,7)0,218## Chi-Square Test ** Mann-Whitney U TestGD: Graves DiseaseTED: Thyroid Eye DiseaseT3: Triiodothyronine T4: Thyroxine ng/L: nanogram/literTSH: Thyroid-Stimulating Hormone mU/L: milli-unit/literTRAb: TSH receptor antibodies IU/L: international unit/literAnti-TPO: Anti-Thyroid Peroxidase antibody kU/L: 1000 IU/LAnti-TG: Anti-Thyroglobulin antibodyIgG4: Immunoglobulin G4 mg/dL: milligram/deciliterMean ± SD (Min–Max): Mean±Standard Deviation (Minimum–Maximum)Reference ranges: free T3, 2.0–4.4 ng/L; free T4, 8.9–17.1 ng/L; TSH, 0.27–4.2 mU/L; TRAb, < 1.75 IU/L; anti-TPO, < 34 kU/L; anti-Tg, < 115 kU/L; total IgG, 767–1590 mg/dL Laboratory values # Chi-Square Test ** Mann-Whitney U Test GD: Graves Disease TED: Thyroid Eye Disease T3: Triiodothyronine T4: Thyroxine ng/L: nanogram/liter TSH: Thyroid-Stimulating Hormone mU/L: milli-unit/liter TRAb: TSH receptor antibodies IU/L: international unit/liter Anti-TPO: Anti-Thyroid Peroxidase antibody kU/L: 1000 IU/L Anti-TG: Anti-Thyroglobulin antibody IgG4: Immunoglobulin G4 mg/dL: milligram/deciliter Mean ± SD (Min–Max): Mean±Standard Deviation (Minimum–Maximum) Reference ranges: free T3, 2.0–4.4 ng/L; free T4, 8.9–17.1 ng/L; TSH, 0.27–4.2 mU/L; TRAb, < 1.75 IU/L; anti-TPO, < 34 kU/L; anti-Tg, < 115 kU/L; total IgG, 767–1590 mg/dL Distribution of serum IgG4 levels in patients with and without thyroid eye disease (TED) (p = 0.041) In the group of patients who developed TED, cases stratified according to disease severity based on the EUGOGO criteria were compared in terms of epidemiological, laboratory, and clinical characteristics in Table 2. With regard to gender distribution, the proportion of men was significantly higher in the moderate-to-severe TED group compared with the mild group (66.7% vs. 12.5%; p = 0.013), whereas women predominated in the mild group. The mean age was significantly higher in the moderate-to-severe TED group (47.80 ± 10.03 years) than in the mild group (37.50 ± 13.09 years) (p = 0.048). Serum IgG4 levels and the IgG4/total IgG ratio were significantly higher in the moderate-to-severe TED group compared with the mild group (p = 0.042 and p = 0.041, respectively), while total IgG levels were similar between the two groups (p = 0.771)(Fig. 2). The proportion of patients with serum IgG4 levels ≥ 135 mg/dL was 12.5% (n = 1) in the mild group and 26.7% (n = 4) in the moderate-to-severe group; however, this difference was not statistically significant (p = 0.433). Table 2Epidemiological, laboratory and clinical features in the severity staging of the TED patient groupThyroid Eye Disease SeverityMild =8Moderate-to-Severe =15Mean±SD (Min–Max)Mean±SD (Min–Max)pGender n (%)Male1a (12,5)10b (66,7)0,013Female7a(87,5)5b (33,3)Age37,50±13,09 (18-58)47,80±10,03 (24-60)0,048*Smoking n (%)4 (50,0)9 (60,0),645#Thyroidectomy n (%)1 (12,50)5 (33,3) 0,278#Free T3 ng/L3,55±0,76 (2,57-4,64)6,07±5,39 (1,72-18,70)0,478Free T4 ng/L10,31±2,72 (7,39-14,80)17,26±11,05 (3,95-47)0,061TSH mU/L2,45±3,34 (0,01-10)3,78±8,93 (0,01-27)0,210TRAb IU/L3,23±3,27 (0,1-8)8,98±13,06 (0,1-40)0,383Anti-TPO kU/L155,81±208,16 (9-600)214,86±184,32 (9-600)0,381Anti-TG kU/L263,78±294,83 (13,4-912)1127,75±1544,31 (12,1-4000)0,438IgG4 mg/dL 55,79±49,87 (0,6-164)120,01±103,37 (32,3-380)0,042Total IgG mg/dL1243,50±195,73 (948-1530)1226,13±276,42 (768-1710)0,771IgG4/IgG Total (%) 4,84±4,80 (0,05-15,05)9,77±7,15 (1,99-23,09)0,041IgG4 ≥135 mg/dL n(%)1 (12,5)4 (26,7),433#Right Hertel mm21,63±2,13(19-25)27,13±2,20 (24-30)<0,001Left Hertel mm21,63±1,60 (19-24)26,53±2,26 (22-30)<0,001Right Vision (Snellen)1,00±0,00 (1-1)0,97±0,09 (0,7-1)0,291Left Vision (Snellen)1,00±0,00 (1-1)0,95±0,15 (0,5-1)0,291Right IOP mmHg17,38±2,33 (14-22)20,20±6,18 (13-36)0,299Left IOP mmHg17,50±2,62 (14-23)19,80±3,80 (15-27)0,117CAS1,25±0,89 (0-2)3,47±1,30 (1-5)<0,001# Chi-square Test * Student’s t-test ** Mann-Whitney U TestTED: Thyroid Eye Disease T3: Triiodothyronine T4: Thyroxine ng/L: nanogram/literTSH: Thyroid Stimulating Hormone mU/L: milliunit/liter TRAb: TSH receptor antibodies IU/L: international unit/liter Anti-TPO: Anti-Thyroid Peroxidase antibody kU/L: 1000 IU/L Anti-TG: Anti-Thyroglobulin antibody IgG4: Immunoglobulin G4 mg/dL: milligram/deciliter Mean ± SD (Min–Max): Mean±Standard Deviation (Minimum–Maximum) IOP: Intraocular Pressure mm: millimeter CAS: Clinical Activity ScoreReference ranges: free T3, 2.0–4.4 ng/L; free T4, 8.9–17.1 ng/L; TSH, 0.27–4.2 mU/L; TRAb, <1.75 IU/L; anti-TPO, <34 kU/L; anti-Tg, <115 kU/L; total IgG, 767–1590 mg/dL Epidemiological, laboratory and clinical features in the severity staging of the TED patient group # Chi-square Test * Student’s t-test ** Mann-Whitney U Test TED: Thyroid Eye Disease T3: Triiodothyronine T4: Thyroxine ng/L: nanogram/literTSH: Thyroid Stimulating Hormone mU/L: milliunit/liter TRAb: TSH receptor antibodies IU/L: international unit/liter Anti-TPO: Anti-Thyroid Peroxidase antibody kU/L: 1000 IU/L Anti-TG: Anti-Thyroglobulin antibody IgG4: Immunoglobulin G4 mg/dL: milligram/deciliter Mean ± SD (Min–Max): Mean±Standard Deviation (Minimum–Maximum) IOP: Intraocular Pressure mm: millimeter CAS: Clinical Activity Score Reference ranges: free T3, 2.0–4.4 ng/L; free T4, 8.9–17.1 ng/L; TSH, 0.27–4.2 mU/L; TRAb, <1.75 IU/L; anti-TPO, <34 kU/L; anti-Tg, <115 kU/L; total IgG, 767–1590 mg/dL Distribution of serum IgG4 levels in patients with mild and moderate-to-severe thyroid eye disease (TED) (p = 0.042) In the evaluation performed using the CAS, patients who developed TED were compared as active (n = 12) and inactive (n = 11) in terms of epidemiological, laboratory, and clinical characteristics in Table 3. Serum IgG4 levels were found to be significantly higher in the active group compared with the inactive group (132.02 ± 112.13 mg/dL vs. 60.21 ± 45.43 mg/dL; p = 0.049)(Fig. 3). In contrast, no significant differences were observed between the groups with respect to total IgG levels and the IgG4/IgG ratio (p = 0.878 and p = 0.065, respectively). The proportion of patients with serum IgG4 ≥ 135 mg/dL was 33.3% in the active group and 9.1% in the inactive group; however, this difference was not statistically significant (p = 0.159). Table 3Epidemiological, laboratory and clinical features according to activity in thyroid eye diseaseThyroid Eye Disease ActivityCAS<3 (inactive) = 11CAS ≥3 (active) = 12Mean±SD (Min–Max)Mean±SD (Min–Max)pGender n (%)Male 4a (36,4)7b (58,3)0,292#Female 7a (63,6)5b (41,7) Age 37,09±12,58 (18-58) 50,75±6,80 (34-60) 0,005* Smoking n (%)5 (45,5)8 (66,7)0,305#Thyroidectomy n (%)2 (18,2)4 (33,3)0,408#Free T3 ng/L4,98±4,61 (2,57-18,7)5,39±4,58 (1,72-17,80)0,951Free T4 ng/L14,62±11,21 (7,39-47)15,05±8,29 (3,95-30,0)0,460TSH mU/L2,01±2,96 (0,01-10,3)4,52±9,91 (0,01-26,60)0,330TRAb IU/L6,53±11,50 (0,1-40)7,39±10,90 (0,1-40)0,538Anti-TPO kU/L205,23±220,19 (9-600)184,33±167,81 (9-412)0,951Anti-TG kU/L356,47±352,12 (13,4-1041)1258,78±1705,05 (12,1-4000)0,853 IgG4 mg/dL 60,21±45,43 (42,8-164) 132,02±112,13 (0,6-380) 0,049 Total IgG mg/dL1235,09±237,64 (858-1620)1229,50±265,36 (768-1710)0,878 IgG4/IgG Total (%) 5,43±4,72 (0,05-15,05)10,46±7,60 (3,42-23,09)0,065IgG4 ≥135 mg/dL n(%)1 (9, 1)4 (33,3),159# Right Hertel mm 22,91±2,98 (19-28) 27,33±2,27 (24-30) 0,002 Left Hertel mm 22,82±2,60 (19-28) 26,67±2,39 (22-30) 0,003 Right Vision (Snellen)1,00±0,00 (1-1)0,96±0,10 (0,7-1)0,166Left Vision (Snellen)1,00±0,00 (1-1)0,93±0,16 (0,5-1)0,166Right IOP mmHg17,09±6,1 (14-22)18,1±4,3 (13-36)0,083 Left IOP mmHg 19,9±2,30 (14-23) 21,17±6,51 (16-27) 0,009 # Chi-square Test * Student’s t-test ** Mann-Whitney U TestTED: Thyroid Eye Disease, T3: Triiodothyronine T4: Thyroxine ng/L: nanogram/liter TSH: Thyroid Stimulating Hormone mU/L: milliunit/liter TRAb: TSH receptor antibodies IU/L: international unit/liter Anti-TPO: Anti-Thyroid Peroxidase antibody kU/L: 1000 IU/L Anti-TG: Anti-Thyroglobulin antibody IgG4: Immunoglobulin G4 mg/dL: milligram/deciliter Mean ± SD (Min–Max): Mean ± Standard Deviation (Minimum – Maximum) IOP: Intraocular Pressure mm: millimeter CAS: Clinical Activity ScoreReference ranges: free T3, 2.0–4.4 ng/L; free T4, 8.9–17.1 ng/L; TSH, 0.27–4.2 mU/L; TRAb, <1.75 IU/L; anti-TPO, <34 kU/L; anti-Tg, <115 kU/L; total IgG, 767–1590 mg/dL. Epidemiological, laboratory and clinical features according to activity in thyroid eye disease # Chi-square Test * Student’s t-test ** Mann-Whitney U Test TED: Thyroid Eye Disease, T3: Triiodothyronine T4: Thyroxine ng/L: nanogram/liter TSH: Thyroid Stimulating Hormone mU/L: milliunit/liter TRAb: TSH receptor antibodies IU/L: international unit/liter Anti-TPO: Anti-Thyroid Peroxidase antibody kU/L: 1000 IU/L Anti-TG: Anti-Thyroglobulin antibody IgG4: Immunoglobulin G4 mg/dL: milligram/deciliter Mean ± SD (Min–Max): Mean ± Standard Deviation (Minimum – Maximum) IOP: Intraocular Pressure mm: millimeter CAS: Clinical Activity Score Reference ranges: free T3, 2.0–4.4 ng/L; free T4, 8.9–17.1 ng/L; TSH, 0.27–4.2 mU/L; TRAb, <1.75 IU/L; anti-TPO, <34 kU/L; anti-Tg, <115 kU/L; total IgG, 767–1590 mg/dL. Distribution of serum IgG4 levels in patients with inactive and active thyroid eye disease (TED) (p = 0.049) In the 23 patients who developed TED, the relationships between serum IgG4 levels and clinical, laboratory, and ophthalmological parameters were examined in Table 4. Correlation analysis demonstrated a significant positive association between serum IgG4 levels and the Clinical Activity Score (CAS ≥ 3; r = 0.420, p = 0.046), as well as disease severity (r = 0.434, p = 0.039). Table 4Correlation of IGG4 levels with epidemiological, laboratory and clinical parameters in 23 patients who developed TEDIgG4 mg/dL r p Age-0.1550.480Duration of GravesThyroidectomy0.129-0.2460.5580.257Right Hertel mm-0.0090.968Left Hertel mm-0.0350.875Right Vision (Snellen)0.2120.331Left Vision (Snellen)0.2060.345Free T3 ng/L0.2010.357Free T4 ng/L0.1210.584 TSH mU/L -0.425* 0.043 TRAb IU/L0.2690.214Anti-TPO kU/L0.3700.083Anti-TG kU/L0.0230.916Total IgG mg/dL-0.2610.228CASLower Lid Retraction0.2410.1630.2670.458Upper Lid Retraction0.3200.137 CAS ≥ 3 (Active) 0.420* 0.046 Diplopia-0.0930.674Proptosis0.0360.872Extraocular Muscle Involvement-0.0670.761 Severity 0.434* 0.039 Spearman Correlation TestTED: Thyroid Eye Disease, T3: Triiodothyronine T4: Thyroxine ng/L: nanogram/literTSH: Thyroid Stimulating Hormone mU/L: milliunit/literTRAb: TSH receptor antibodies IU/L: international unit/literAnti-TPO: Anti-Thyroid Peroxidase antibody kU/L: 1000 IU/LAnti-TG: Anti-Thyroglobulin antibodyIgG4: Immunoglobulin G4 mg/dL: milligram/deciliterCAS: Clinical Activity Score Correlation of IGG4 levels with epidemiological, laboratory and clinical parameters in 23 patients who developed TED Duration of Graves Thyroidectomy 0.129 -0.246 0.558 0.257 CAS Lower Lid Retraction 0.241 0.163 0.267 0.458 Spearman Correlation Test TED: Thyroid Eye Disease, T3: Triiodothyronine T4: Thyroxine ng/L: nanogram/liter TSH: Thyroid Stimulating Hormone mU/L: milliunit/liter TRAb: TSH receptor antibodies IU/L: international unit/liter Anti-TPO: Anti-Thyroid Peroxidase antibody kU/L: 1000 IU/L Anti-TG: Anti-Thyroglobulin antibody IgG4: Immunoglobulin G4 mg/dL: milligram/deciliter CAS: Clinical Activity Score Discussion This study is among the limited number of investigations evaluating the role of IgG4 across the disease spectrum by comparing serum IgG, IgG4, and IgG4/IgG ratios between patients who did and did not develop TED, as well as across mild–moderate/severe and active–inactive subgroups. In this respect, the present study contributes to the literature as one of the few single-cohort analyses providing a comprehensive evaluation of the relationship between IgG4 and the clinical spectrum and activity dynamics of TED. While no significant difference in total IgG levels was observed between the groups, both serum IgG4 levels and the IgG4/IgG ratio were significantly higher in patients who developed TED, particularly in the moderate-to-severe TED subgroup. In patients with active TED, serum IgG4 levels were significantly higher compared with inactive patients, whereas no significant difference was observed in the IgG4/IgG ratio. These findings suggest that serum IgG4 levels may represent a biochemical marker associated with the development, activity, and severity of TED. Bozkırlı et al. [7] reported that serum IgG4 levels were significantly higher in patients with Graves’ disease compared with healthy controls, with this increase being particularly prominent in the TED-positive subgroup. This early observation suggested that IgG4 may not merely reflect the autoimmune thyroid response, but could also serve as a serological marker associated with orbital involvement. Similarly, Yu et al. [11] demonstrated that serum IgG4 levels and the IgG4/IgG ratio were associated with the development of TED in newly diagnosed Graves’ disease patients, whereas total IgG levels did not differ. Luo et al. [15] also reported significantly elevated IgG4 levels in patients with TED compared with controls, and further showed associations with TRAb levels and bilateral extraocular muscle thickening. With respect to disease activity, Zhao et al. [12] reported that both serum IgG4 levels and the IgG4/IgG ratio were significantly increased in active TED, while Olejarz et al. [16] demonstrated significantly elevated serum IgG4 levels in active disease in a study supported by MRI confirmation. This imaging-validated approach suggests that serum IgG4 levels may be more closely associated with clinically active inflammatory phases. In contrast, Deng et al. [17] reported in a longitudinal cohort that the IgG4/IgG ratio was associated with the development of TED but did not correlate with ocular activity. These discrepancies may be attributable to differences in activity definitions (CAS vs. CAS combined with MRI), sampling timing, and methodological variations in IgG4 measurement (≥ 135 mg/dL vs. ≥8%, ELISA vs. turbidimetric methods). Within this context, the present study offers three main contributions to the literature. First, by focusing not only on the presence of TED but also on activity and severity subgroups, it systematically characterizes the behavior of IgG4 across the clinical spectrum. Second, by evaluating the IgG4/IgG ratio, the study demonstrates that this parameter does not independently reflect disease activity, a finding consistent with the series reported by Deng et al. [17], suggesting that the ratio should not be used as a sole determinant in clinical decision-making. Third, by selecting the control group from Graves’ disease patients without TED rather than healthy individuals, the study minimizes differences in autoimmune background and more clearly isolates the component of IgG4 elevation associated with orbital involvement. In this regard, the present design provides a methodologically stronger comparative framework than those used by Bozkırlı et al. [7] and Luo et al. [15] Overall, while the studies by Bozkırlı [7], Yu [11], and Luo [15] delineate a characteristic serological profile linking IgG4 to the presence of TED, the findings of Zhao [12] and Olejarz [13] indicate that this profile becomes more pronounced during periods of active inflammation, whereas Deng [17] suggests that risk of development and activity indicators do not always overlap. Consistent with this general pattern, our findings indicate that serum IgG4 levels are associated with the presence and severity of TED, but may provide conditional rather than absolute utility for activity monitoring. Accordingly, we suggest that the IgG4/IgG ratio should not be used as a standalone marker in clinical decision-making. From a clinical perspective, serum IgG4 measurement may be considered a supportive parameter for risk stratification and phenotyping in TED; however, standardization of CAS ± MRI-based activity definitions and prospective multicenter studies are required to clarify its role in activity monitoring and prediction of treatment response. The serum IgG4 threshold of ≥ 135 mg/dL is widely accepted as a biochemical criterion in the diagnosis of IgG4-related disease (IgG4-RD) and is similarly applied in IgG4-related orbital disease (IgG4-ROD). [8–9] In the present study, the proportion of patients meeting this threshold was 8.7% among those without TED, 21.7% among those with TED, 33.3% among active patients, and 26.7% among moderate-to-severe cases. Although these subgroup differences were not statistically significant, these rates were largely consistent with those reported in the literature (Bozkırlı 37.5% [7]; Sy 20.8% [18]; Luo 16% [15]; Olejarz 25% [13]; Zhao 27.5% [12]). In contrast, Comi et al. [14] did not identify differences between TED and non-TED Graves’ disease patients using ≥ 135 mg/dL or IgG4/IgG ≥ 8% thresholds, possibly reflecting population-specific or methodological factors that may obscure subgroup differences. Therefore, these findings should be interpreted cautiously and considered hypothesis-generating rather than confirmatory. These findings indicate that serum IgG4 levels in a subset of TED patients may exceed the biochemical thresholds defined for IgG4-RD. Nevertheless, given the requirement for histopathological confirmation in the diagnosis of IgG4-related orbital disease, elevated serum IgG4 alone is not diagnostic. In this context, the ≥ 135 mg/dL threshold should be regarded not as a diagnostic criterion, but rather as an indicator of immunological heterogeneity within the TED spectrum that may aid in the identification of potential biochemical subgroups. Male sex and older age were associated with moderate-to-severe TED in our cohort. Although TED is generally more prevalent in women, disease prevalence and disease severity represent distinct clinical characteristics, and previous studies have reported a more severe disease course in men. Proposed explanations include greater cumulative smoking exposure, age-related changes in immune regulation, and sex-related differences in immune responses. Similarly, older age has been associated with a more severe TED phenotype, suggesting that age may influence disease severity rather than susceptibility alone [19]. Although smoking status did not differ significantly between severity subgroups in our study, its potential contribution cannot be excluded given the limited sample size. Overall, our findings are consistent with previous reports suggesting that demographic factors may influence TED severity. [3–4] In our study, serum IgG4 levels showed a positive correlation with disease activity and severity, whereas no significant association was observed with CAS. This finding suggests that IgG4 may reflect biological disease activity independently of conventional clinical scoring. Similarly, Olejarz et al. [16] reported no correlation between serum IgG4 levels and CAS, proposing that IgG4 elevation may be related to subclinical tissue inflammation and fibroinflammatory processes. Strengths of the Study. This study provides a meaningful contribution to the limited body of literature by comprehensively evaluating the association between serum IgG4 levels and the development, severity, and activity of TED within the same cohort of patients with Graves’ disease. The selection of the control group from Graves’ disease patients without TED, rather than healthy individuals, minimized variability related to the autoimmune background and allowed a clearer characterization of the biological component of IgG4 elevation associated with orbital involvement. The combined evaluation of both absolute serum IgG4 levels and the IgG4/IgG ratio enabled a more balanced and comprehensive assessment of the role of the IgG4 response within the spectrum of TED. Furthermore, the use of standardized clinical, ophthalmological, and biochemical assessment protocols enhanced methodological consistency. Limitations. The single-center design and relatively limited sample size restrict the generalizability of the findings and limited the ability to derive reliable diagnostic cutoff values or perform robust multivariable analyses. In addition, serum IgG4 levels were measured at a single time point, precluding evaluation of biomarker dynamics during the disease course and their relationship with disease progression or treatment response. Histopathological confirmation was not performed, limiting the ability to fully exclude potential biological overlap with IgG4-related orbital disease (IgG4-ROD). Furthermore, clinical activity was assessed solely using the CAS without imaging-based inflammatory markers, making it difficult to determine whether elevated serum IgG4 levels primarily reflect active inflammation or later fibroinflammatory changes. Finally, serum vitamin D levels were not evaluated and may have influenced immune regulation and IgG4 responses. Future longitudinal studies incorporating imaging, immunomodulatory factors, and larger patient cohorts are needed to further clarify these findings. Conclusion In conclusion, serum IgG4 levels may emerge as a parameter associated with biological disease activity in TED, independent of the Clinical Activity Score. Beyond conventional clinical scoring systems, serum IgG4 may have the potential to reflect subclinical inflammatory burden and inflammatory processes within orbital tissues. In this context, measurement of serum IgG4 may be considered a complementary biomarker candidate for assessing TED presence, activity, and severity and supporting immunological phenotyping in patients with Graves’ disease. To validate this approach, prospective studies evaluating serum IgG4 levels alongside radiological activity markers (MRI-based assessments) and tissue biomarkers, such as fibrosis and hyaluronan accumulation, are needed. In particular, longitudinal studies assessing IgG4 dynamics before and after treatment may further clarify the potential role of this parameter in disease activity assessment and prediction of treatment response. Acknowledgements Not applicable. Author contributions DM: Data collection, writing – review & editing, writing – original draft, visualization. AY: Writing – original draft, writing – review & editing, visualization. ÖD: Data collection, visualization. FÖ: Data collection, visualization. All authors read and approved the final manuscript. Funding The authors funded this study and did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study protocol was reviewed and approved by the Clinical Research Ethics Committee of SBÜ Haseki Training and Research Hospital with the decision dated 06.12.2023 and numbered 215–2023. This research complied with the principles of the Declaration of Helsinki. Informed consent forms were obtained from all participants. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.